Find Ofloxacin manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Related ProductsRelated Products

Synopsis

0 DRUGS IN DEVELOPMENT

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

161RELATED EXCIPIENT COMPANIES

250EXCIPIENTS BY APPLICATIONS

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

GLOBAL SALES INFORMATION

Annual Reports

NA

MARKET PLACE

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 82419-36-1, Floxin, Tarivid, Ofloxacine, Oxaldin, Ocuflox
Molecular Formula
C18H20FN3O4
Molecular Weight
361.4  g/mol
InChI Key
GSDSWSVVBLHKDQ-UHFFFAOYSA-N
FDA UNII
A4P49JAZ9H

Ofloxacin
A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.
Ofloxacin is a Quinolone Antimicrobial.
1 2D Structure

Ofloxacin

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
7-fluoro-2-methyl-6-(4-methylpiperazin-1-yl)-10-oxo-4-oxa-1-azatricyclo[7.3.1.05,13]trideca-5(13),6,8,11-tetraene-11-carboxylic acid
2.1.2 InChI
InChI=1S/C18H20FN3O4/c1-10-9-26-17-14-11(16(23)12(18(24)25)8-22(10)14)7-13(19)15(17)21-5-3-20(2)4-6-21/h7-8,10H,3-6,9H2,1-2H3,(H,24,25)
2.1.3 InChI Key
GSDSWSVVBLHKDQ-UHFFFAOYSA-N
2.1.4 Canonical SMILES
CC1COC2=C3N1C=C(C(=O)C3=CC(=C2N4CCN(CC4)C)F)C(=O)O
2.2 Other Identifiers
2.2.1 UNII
A4P49JAZ9H
2.3 Synonyms
2.3.1 MeSH Synonyms

1. Dl 8280

2. Dl-8280

3. Dl8280

4. Dr 3355

5. Dr-3355

6. Dr3355

7. Hoe 280

8. Hoe-280

9. Hoe280

10. Ofloxacin Hydrochloride

11. Ofloxacine

12. Orf 28489

13. Orf-28489

14. Orf28489

15. Ru 43280

16. Ru-43280

17. Ru43280

18. Tarivid

2.3.2 Depositor-Supplied Synonyms

1. 82419-36-1

2. Floxin

3. Tarivid

4. Ofloxacine

5. Oxaldin

6. Ocuflox

7. Hoe-280

8. Oflx

9. Dl-8280

10. Ofloxacino

11. Ofloxacinum

12. Exocin

13. Hoe 280

14. Floxin Otic

15. Dextrofloxacin

16. 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7h-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic Acid

17. 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-3,7-dihydro-2h-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic Acid

18. Chebi:7731

19. Oflocet

20. Visiren

21. Chembl4

22. J01ma01

23. Nsc-727071

24. Nsc-758178

25. A4p49jaz9h

26. Mls000028749

27. Ofloxacina

28. Ofloxacin Otic

29. Ofloxacina [dcit]

30. Ofloxacine [french]

31. Ofloxacinum [latin]

32. Exocine

33. Flobacin

34. Ofloxacin 100 Microg/ml In Acetonitrile

35. Smr000058192

36. Zanocin

37. Floxil

38. Ofloxacino [spanish]

39. Dsstox_cid_21085

40. Dsstox_rid_79623

41. Dsstox_gsid_41085

42. 8-fluoro-3-methyl-9-(4-methyl-piperazin-1-yl)-6-oxo-2,3-dihydro-6h-1-oxa-3a-aza-phenalene-5-carboxylic Acid

43. Ofx

44. Floxin In Dextrose 5%

45. Dl 8280

46. Pt 01

47. Orf 18489

48. (-)-(s)-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7h-pyrido[1,2,3-de]-1;(-)-(s)-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7h-pyrido[1,2,3-de]-1

49. 9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7h-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic Acid

50. Floxin (tn)

51. Ccris 5233

52. (+/-)-floxin

53. Sr-01000076050

54. Mfcd00226105

55. Unii-a4p49jaz9h

56. Floxin In Dextrose 5% In Plastic Container

57. Brn 3657947

58. Monoflocet

59. Dl-ofloxacin

60. Hsdb 8030

61. Ofloxacin,(s)

62. Ncgc00016948-01

63. Ofloxacin (floxin)

64. Cas-82419-36-1

65. Dl8280

66. Exocin (eye Drops)

67. Ofloxacin [usan:usp:inn:ban:jan]

68. (+-)-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7h-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic Acid

69. 83380-47-6

70. Wp-0405

71. Spectrum_001186

72. Ofloxacin [inn]

73. Ofloxacin [jan]

74. Ofloxacin [mi]

75. (r)-ofloxacin-[d3]

76. Ofloxacin [usan]

77. Opera_id_1114

78. Prestwick0_000237

79. Prestwick1_000237

80. Prestwick2_000237

81. Prestwick3_000237

82. Spectrum2_001464

83. Spectrum3_001499

84. Spectrum4_000324

85. Spectrum5_001063

86. Ofloxacin [vandf]

87. Epitope Id:116889

88. Ofloxacin [mart.]

89. O 8757

90. Ofloxacin [usp-rs]

91. Ofloxacin [who-dd]

92. Lopac0_000904

93. Oprea1_242882

94. Schembl24373

95. Bspbio_000313

96. Bspbio_003117

97. Kbiogr_000667

98. Kbioss_001666

99. Fluoro-methyl-(4-methylpiperazin-1-yl)-oxo-[?]carboxylic Acid

100. Mls001074203

101. Mls006011774

102. Divk1c_000721

103. Spectrum1502044

104. Spbio_001387

105. Spbio_002234

106. (s)-ofloxacin;levaquin;quixin

107. Ofloxacin (jp17/usp/inn)

108. Bpbio1_000345

109. Ofloxacin [orange Book]

110. Dtxsid3041085

111. Ofloxacin [ep Monograph]

112. Schembl14163982

113. Gtpl10918

114. Hms502e03

115. Kbio1_000721

116. Kbio2_001666

117. Kbio2_004234

118. Kbio2_006802

119. Kbio3_002617

120. Ofloxacin [usp Monograph]

121. Chebi:194135

122. Ninds_000721

123. Hms1568p15

124. Hms1921h12

125. Hms2090f07

126. Hms2092b10

127. Hms2095p15

128. Hms2235c05

129. Hms3259g07

130. Hms3262f10

131. Hms3369b01

132. Hms3393k06

133. Hms3604b17

134. Hms3712p15

135. Pharmakon1600-01502044

136. (3r)-9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7h-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic Acid

137. (s)-9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-3,7-dihydro-2h-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic Acid

138. Amy22220

139. Bcp14346

140. Bcp22048

141. Hy-b0125

142. Rkl10083

143. Ofloxacin, Fluoroquinolone Antibiotic

144. Tox21_110703

145. Tox21_500904

146. Bbl005605

147. Bdbm50045004

148. Ccg-39210

149. Nsc727071

150. Nsc758178

151. S1463

152. Stk256723

153. Ofloxacin 100 Microg/ml In Methanol

154. Akos001033517

155. Akos016042783

156. Ofloxacine; Dl-8280; Hoe-280

157. Tox21_110703_1

158. Ac-7616

159. Bcp9000851

160. Cs-1891

161. Db01165

162. Ks-5011

163. Lp00904

164. Nc00466

165. Nsc 727071

166. Nsc 758178

167. Sdccgsbi-0050879.p004

168. Idi1_000721

169. Ncgc00015772-02

170. Ncgc00015772-03

171. Ncgc00015772-04

172. Ncgc00015772-05

173. Ncgc00015772-06

174. Ncgc00015772-07

175. Ncgc00015772-08

176. Ncgc00015772-09

177. Ncgc00015772-10

178. Ncgc00015772-12

179. Ncgc00015772-13

180. Ncgc00015772-22

181. Ncgc00094219-01

182. Ncgc00094219-02

183. Ncgc00094219-03

184. Ncgc00094219-04

185. Ncgc00094219-05

186. Ncgc00094219-06

187. Ncgc00178284-01

188. Ncgc00178284-02

189. Ncgc00261589-01

190. (+-)-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7h-pyrido(1,2,3-de)(1,4)benzoxazin-6-carbonsaeure

191. (+/-)-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7h-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic Acid

192. 7h-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic Acid, 2,3-dihydro-9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-, (+-)-

193. 7h-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic Acid, 9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-, (+-)-

194. 9-fluoro-3,7-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2h-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic Acid

195. Sy007392

196. Sbi-0050879.p003

197. Db-056608

198. Ab00513820

199. Eu-0100904

200. Ft-0627808

201. Ft-0630905

202. Ft-0670773

203. Ft-0673216

204. O0403

205. Ofloxacin, Vetranal(tm), Analytical Standard

206. Vu0243192-7

207. 86o854

208. C07321

209. D00453

210. O-2800

211. Ab00052263-12

212. Ab00052263-13

213. Ab00052263_14

214. Ab00052263_15

215. Ofloxacin, Antibiotic For Culture Media Use Only

216. A864414

217. Q411447

218. Sr-01000076050-1

219. Sr-01000076050-4

220. Sr-01000076050-7

221. Brd-a24228527-001-05-9

222. Brd-a24228527-001-19-0

223. Sr-01000076050-16

224. Z56761309

225. F0020-0095

226. F0472-0226

227. 7-chloro-4-hydroxy-8-methylquinoline-3-carboxylicethylester

228. Ofloxacin, European Pharmacopoeia (ep) Reference Standard

229. Ofloxacin, United States Pharmacopeia (usp) Reference Standard

230. (+/-)-9-fluoro-2,2,3-de)-1,4-benzoxazine-6-carboxylic Acid

231. 8-methyl-2,3-dihydrofuro[3,2-e]imidazo-[1,2-c]pyrimidine-9-carboxylicacid

232. Ofloxacin, Pharmaceutical Secondary Standard; Certified Reference Material

233. (+/-)-9-fluoro-2, 3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7h-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic Acid

234. 7-fluoro-2-methyl-6-(4-methylpiperazin-1-yl)-10-oxo-4-oxa-1-azatricyclo[7.3.1.0^{5,13}]trideca-5(13),6,8,11-tetraene-11-carboxylic Acid

235. 7-fluoro-2-methyl-6-(4-methylpiperazin-1-yl)-10-oxo-4-oxa-1-azatricyclo[7.3.1.05,13]trideca-5,7,9(13),11-tetraene-11-carboxylic Acid

236. 7h-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic Acid, 9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-

237. 7h-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic Acid, 9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-, (+/-)-

238. 9-fluoro-10-(4-methylpiperazino)-3-methyl-7-oxo-2,3-dihydro-7h-pyrido[1,2,3-de]-1,4-benzooxazine-6-carboxylic Acid

239. 9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7h-pyrido(1,2,3-de)(1,4)benzoxazine-6-carboxylic Acid, Dl-

240. 9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7h-pyrido [1,2,3-de]-1,4-benzoxazin-6-carboxylic Acid

241. 9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7h-pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylic Acid

242. 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-3,7-dihydro-2h-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylicacid

243. 9-fluoro-3-methyl-10-(4-methylpiperazino)-7-oxo-2,3-dihydro-7h-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic Acid

2.4 Create Date
2005-03-25
3 Chemical and Physical Properties
Molecular Weight 361.4 g/mol
Molecular Formula C18H20FN3O4
XLogP3-0.4
Hydrogen Bond Donor Count1
Hydrogen Bond Acceptor Count8
Rotatable Bond Count2
Exact Mass361.14378429 g/mol
Monoisotopic Mass361.14378429 g/mol
Topological Polar Surface Area73.3 Ų
Heavy Atom Count26
Formal Charge0
Complexity634
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count1
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Information
1 of 6  
Drug NameFloxin otic
PubMed HealthOfloxacin (Into the ear)
Drug ClassesAntibacterial
Drug LabelOCUFLOX (ofloxacin ophthalmic solution) 0.3% is a sterile ophthalmic solution. It is a fluorinated carboxyquinolone anti-infective for topical ophthalmic use....
Active IngredientOfloxacin
Dosage FormSolution/drops
RouteOtic
Strength0.3%
Market StatusPrescription
CompanyDaiichi

2 of 6  
Drug NameOcuflox
PubMed HealthOfloxacin (Into the eye)
Drug ClassesAntibiotic
Drug LabelTo reduce the development of drug-resistant bacteria and maintain the effectiveness of ofloxacin tablets and other antibacterial drugs, ofloxacin tablets should be used only to treat or prevent infections that are proven or strongly suspected to be c...
Active IngredientOfloxacin
Dosage FormSolution/drops
RouteOphthalmic
Strength0.3%
Market StatusPrescription
CompanyAllergan

3 of 6  
Drug NameOfloxacin
PubMed HealthOfloxacin
Drug ClassesAntibacterial, Antibiotic
Active IngredientOfloxacin
Dosage FormSolution/drops; Tablet
RouteOphthalmic; Oral; Otic
Strength200mg; 400mg; 300mg; 0.3%
Market StatusPrescription
CompanyTeva; Cadila Pharms; Apotex; Altaire Pharms; Hi Tech Pharma; Bausch And Lomb; Alcon Pharms; Fera Pharms; Dr Reddys Labs; Fdc; Akorn

4 of 6  
Drug NameFloxin otic
PubMed HealthOfloxacin (Into the ear)
Drug ClassesAntibacterial
Drug LabelOCUFLOX (ofloxacin ophthalmic solution) 0.3% is a sterile ophthalmic solution. It is a fluorinated carboxyquinolone anti-infective for topical ophthalmic use....
Active IngredientOfloxacin
Dosage FormSolution/drops
RouteOtic
Strength0.3%
Market StatusPrescription
CompanyDaiichi

5 of 6  
Drug NameOcuflox
PubMed HealthOfloxacin (Into the eye)
Drug ClassesAntibiotic
Drug LabelTo reduce the development of drug-resistant bacteria and maintain the effectiveness of ofloxacin tablets and other antibacterial drugs, ofloxacin tablets should be used only to treat or prevent infections that are proven or strongly suspected to be c...
Active IngredientOfloxacin
Dosage FormSolution/drops
RouteOphthalmic
Strength0.3%
Market StatusPrescription
CompanyAllergan

6 of 6  
Drug NameOfloxacin
PubMed HealthOfloxacin
Drug ClassesAntibacterial, Antibiotic
Active IngredientOfloxacin
Dosage FormSolution/drops; Tablet
RouteOphthalmic; Oral; Otic
Strength200mg; 400mg; 300mg; 0.3%
Market StatusPrescription
CompanyTeva; Cadila Pharms; Apotex; Altaire Pharms; Hi Tech Pharma; Bausch And Lomb; Alcon Pharms; Fera Pharms; Dr Reddys Labs; Fdc; Akorn

4.2 Therapeutic Uses

Anti-Bacterial Agents; Anti-Infective Agents, Urinary; Nucleic Acid Synthesis Inhibitors

National Library of Medicine's Medical Subject Headings online file (MeSH, 2012)


Ofloxacin is used in the treatment of acute pelvic inflammatory disease (PID) caused by susceptible C. trachomatis or N. gonorrhoeae, but should not be used if QRNG may be involved or if in vitro susceptibility cannot be tested. /Included in US product label/

American Society of Health-System Pharmacists 2011; Drug Information 2011. Bethesda, MD. 2011, p. 407


Ofloxacin is used in adults for the treatment of nongonococcal urethritis and cervicitis caused by Chlamydia trachomatis. /Included in US product label/

American Society of Health-System Pharmacists 2011; Drug Information 2011. Bethesda, MD. 2011, p. 407


Ofloxacin is used in adults for the treatment of uncomplicated urinary tract infections (UTIs) (cystitis) caused by susceptible gram-negative bacteria, including Citrobacter diversus, ... Enterobacter aerogenes, ... Escherichia coli, Klebsiella pneumoniae, ... Proteus mirabilis, or Pseudomonas aeruginosa. /Included in US product label/

American Society of Health-System Pharmacists 2011; Drug Information 2011. Bethesda, MD. 2011, p. 406


For more Therapeutic Uses (Complete) data for Ofloxacin (36 total), please visit the HSDB record page.


4.3 Drug Warning

/BOXED WARNING/ WARNING: Fluoroquinolones, including ofloxacin, are associated with an increased risk of tendinitis and tendon rupture in all ages. This risk is further increased in older patients usually over 60 years of age, in patients taking corticosteroid drugs, and in patients with kidney, heart or lung transplants.

US Natl Inst Health; DailyMed. Current Medication Information for OFLOXACIN tablet, film coated (January 2012). Available from, as of February 28, 2012: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=95b9fc17-9c94-4762-910c-df0bb0b2aa85


/BOXED WARNING/ WARNING: Fluoroquinolones, including ofloxacin, may exacerbate muscle weakness in persons with myasthenia gravis. Avoid ofloxacin in patients with known history of myasthenia gravis.

US Natl Inst Health; DailyMed. Current Medication Information for OFLOXACIN tablet, film coated (January 2012). Available from, as of February 28, 2012: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=95b9fc17-9c94-4762-910c-df0bb0b2aa85


Some quinolones, including ofloxacin, have been associated with prolongation of the QT interval on the electrocardiogram and infrequent cases of arrhythmia. Rare cases of torsade de pointes have been spontaneously reported during postmarketing surveillance in patients receiving quinolones, including ofloxacin.

US Natl Inst Health; DailyMed. Current Medication Information for OFLOXACIN tablet, film coated (January 2012). Available from, as of February 28, 2012: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=95b9fc17-9c94-4762-910c-df0bb0b2aa85


Rare cases of sensory or sensorimotor axonal polyneuropathy affecting small and/or large axons resulting in paresthesias, hypoesthesias, dysesthesias and weakness have been reported in patients receiving quinolones, including ofloxacin. Ofloxacin should be discontinued if the patient experiences symptoms of neuropathy including pain, burning, tingling, numbness, and/or weakness or other alterations of sensation including light touch, pain, temperature, position sense, and vibratory sensation in order to prevent the development of an irreversible condition.

US Natl Inst Health; DailyMed. Current Medication Information for OFLOXACIN tablet, film coated (January 2012). Available from, as of February 28, 2012: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=95b9fc17-9c94-4762-910c-df0bb0b2aa85


For more Drug Warnings (Complete) data for Ofloxacin (28 total), please visit the HSDB record page.


4.4 Drug Indication

For the treatment of infections (respiratory tract, kidney, skin, soft tissue, UTI), urethral and cervical gonorrhoea.


FDA Label


5 Pharmacology and Biochemistry
5.1 Pharmacology

Ofloxacin is a quinolone/fluoroquinolone antibiotic. Ofloxacin is bactericidal and its mode of action depends on blocking of bacterial DNA replication by binding itself to an enzyme called DNA gyrase, which allows the untwisting required to replicate one DNA double helix into two. Notably the drug has 100 times higher affinity for bacterial DNA gyrase than for mammalian. Ofloxacin is a broad-spectrum antibiotic that is active against both Gram-positive and Gram-negative bacteria.


5.2 MeSH Pharmacological Classification

Anti-Infective Agents, Urinary

Substances capable of killing agents causing urinary tract infections or of preventing them from spreading. (See all compounds classified as Anti-Infective Agents, Urinary.)


Anti-Bacterial Agents

Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)


Topoisomerase II Inhibitors

Compounds that inhibit the activity of DNA TOPOISOMERASE II. Included in this category are a variety of ANTINEOPLASTIC AGENTS which target the eukaryotic form of topoisomerase II and ANTIBACTERIAL AGENTS which target the prokaryotic form of topoisomerase II. (See all compounds classified as Topoisomerase II Inhibitors.)


Cytochrome P-450 CYP1A2 Inhibitors

Drugs and compounds which inhibit or antagonize the biosynthesis or actions of CYTOCHROME P-450 CYP1A2. (See all compounds classified as Cytochrome P-450 CYP1A2 Inhibitors.)


5.3 FDA Pharmacological Classification
5.3.1 Active Moiety
OFLOXACIN
5.3.2 FDA UNII
A4P49JAZ9H
5.3.3 Pharmacological Classes
Quinolones [CS]; Quinolone Antimicrobial [EPC]
5.4 ATC Code

J01MA01

S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355


J - Antiinfectives for systemic use

J01 - Antibacterials for systemic use

J01M - Quinolone antibacterials

J01MA - Fluoroquinolones

J01MA01 - Ofloxacin


S - Sensory organs

S01 - Ophthalmologicals

S01A - Antiinfectives

S01AE - Fluoroquinolones

S01AE01 - Ofloxacin


S - Sensory organs

S02 - Otologicals

S02A - Antiinfectives

S02AA - Antiinfectives

S02AA16 - Ofloxacin


5.5 Absorption, Distribution and Excretion

Absorption

Bioavailability of ofloxacin in the tablet formulation is approximately 98%


Route of Elimination

Ofloxacin is mainly eliminated by renal excretion, where between 65% and 80% of an administered oral dose of ofloxacin is excreted unchanged via urine within 48 hours of dosing. About 4-8% of an ofloxacin dose is excreted in the feces and the drug is minimally subject to biliary excretion.


Ofloxacin is distributed into bone, cartilage, bile, skin, sputum, bronchial secretions, pleural effusions, tonsils, saliva, gingival mucosa, nasal secretions, aqueous humor, tears, sweat, lung, blister fluid, pancreatic fluid, ascitic fluid, peritoneal fluid, gynecologic tissue, vaginal fluid, cervix, ovary, semen, prostatic fluid, and prostatic tissue. For most of these tissues and fluids, ofloxacin concentrations are approximately 0.5-1.7 times concurrent serum concentrations. Ofloxacin is concentrated within neutrophils, achieving concentrations in these cells that may be up to 8 times greater than extracellular concentrations.

American Society of Health-System Pharmacists 2011; Drug Information 2011. Bethesda, MD. 2011, p. 417


Ofloxacin is widely distributed into body tissues and fluids following oral administration. In healthy adults, the apparent volume of distribution of ofloxacin averages 1-2.5 L/kg. Impaired renal function does not appear to affect the volume of distribution of ofloxacin; the apparent volume of distribution of the drug averages 1.1-2 L/kg in patients with impaired renal function, including those with severe renal failure undergoing hemodialysis.

American Society of Health-System Pharmacists 2011; Drug Information 2011. Bethesda, MD. 2011, p. 417


Pharmacokinetic parameters in geriatric patients receiving ofloxacin generally are similar to those in younger adults. Although results of pharmacokinetic studies in geriatric individuals 65-81 years of age indicate that the rate of absorption, volume of distribution, and route of excretion in geriatric individuals are similar to those in younger adults, peak serum concentrations are slightly higher (9-21% higher) and half-life more prolonged in geriatric patients than in younger adults. There also is evidence that peak plasma concentration are higher in geriatric women than geriatric men (114% higher following single doses or 54% higher following multiple doses).

American Society of Health-System Pharmacists 2011; Drug Information 2011. Bethesda, MD. 2011, p. 417


The oral bioavailability of ofloxacin is 85-100% in healthy, fasting adults, and peak serum concentrations of the drug generally are attained within 0.5-2 hours. In patients with normal renal and hepatic function, peak serum concentrations and AUCs increase in proportion to the dose over the oral dosage range of 100-600 mg and generally are unaffected by age. Following oral administration of a single 100-, 200-, 300-, or 400-mg dose of ofloxacin in healthy, fasting adults, peak serum concentrations average 1-1.3, 1.5-2.7, 2.4-4.6, or 2.9-5.6 ug/mL, respectively. Some accumulation occurs following multiple doses. Steady-state serum concentrations of ofloxacin are achieved after 4 doses of the drug and are approximately 40% higher than concentrations achieved following single oral doses.

American Society of Health-System Pharmacists 2011; Drug Information 2011. Bethesda, MD. 2011, p. 417


For more Absorption, Distribution and Excretion (Complete) data for Ofloxacin (18 total), please visit the HSDB record page.


5.6 Metabolism/Metabolites

Hepatic


Less than 10% of a single dose of ofloxacin is metabolized; approximately 3-6% of the dose is metabolized to desmethyl ofloxacin and 1-5% is metabolized to ofloxacin N-oxide. Desmethyl ofloxacin is microbiologically active, but is less active against susceptible organisms than is ofloxacin; ofloxacin N-oxide has only minimal antibacterial activity.

American Society of Health-System Pharmacists 2011; Drug Information 2011. Bethesda, MD. 2011, p. 417


Seven patients with end-stage renal disease on regular hemodialysis were treated orally with a loading dose of 200 mg ofloxacin and multiple maintenance doses of 100 mg per 24 hr for 10 days. The pharmacokinetics of ofloxacin and its metabolites were studied at the end of the treatment period. Plasma and dialysate concentrations of ofloxacin and ofloxacin metabolites were measured by HPLC. Peak (3.1 mg.L-1) and trough levels (1.6 mg.L-1) and the AUC of ofloxacin were comparable to the values in healthy volunteers given 300 to 400 mg ofloxacin p.o. The mean half-life, determined in the dialysis-free interval (t1/2 beta) and during the haemodialysis session (t1/2 HD), was 38.5 h and 9.9 h, respectively. Extrarenal clearance (32.7 mL.min-1) was unchanged as compared to that reported in healthy volunteers after a single dose of ofloxacin. The fractional removal by haemodialysis amounted to 21.5%. Two metabolites, ofloxacin-N-oxide and demethyl-ofloxacin, were detected in plasma. Despite prolonged t1/2 beta of both metabolites (66.1 and 50.9 hr) and multiple doses of ofloxacin the peak concentrations of the metabolites reached only 14% and 5% of that of the parent drug, respectively. It is concluded that in patients on regular hemodialysis treatment the dosage adjustment employed resulted in safe and therapeutically favourable plasma concentrations. The observed accumulation of ofloxacin metabolites does not appear to have any toxic or therapeutic significance.

PMID:1541323 Kampf D et al; Eur J Clin Pharmacol 42 (1): 95-9 (1992)


5.7 Biological Half-Life

9 hours


In adults with creatinine clearances of 10-50 mL/minute, half-life of the drug averages 16.4 hours (range: 11-33.5 hours); in adults with creatinine clearances less than 10 mL/minute, half-life averages 21.7 hours (range: 16.9-28.4 hours). In patients with end-stage renal failure, half-life of the drug may range from 25-48 hours.

American Society of Health-System Pharmacists 2011; Drug Information 2011. Bethesda, MD. 2011, p. 417


In healthy adults with normal renal function, the elimination half-life of ofloxacin in the distribution phase averages 0.5-0.6 hours and the elimination half-life in the terminal phase averages 4-8 hours.In healthy geriatric adults 64-86 years of age with renal function normal for their age, half-life of the drug averages 6.4-8.5 hours.

American Society of Health-System Pharmacists 2011; Drug Information 2011. Bethesda, MD. 2011, p. 417


Following ocular instillation of 1 drop of ofloxacin 0.3% 4 times daily for 12 doses in healthy individuals, the elimination half-life of drug in tear film was approximately 226 minutes. In a study in rabbits, the terminal elimination half-life of ofloxacin in tear film following topical application to the eye was approximately 210 minutes. In adults with normal renal function, the serum elimination half-life of ofloxacin in the terminal phase averages 4-8 hours.

American Society of Health-System Pharmacists 2011; Drug Information 2011. Bethesda, MD. 2011


5.8 Mechanism of Action

Ofloxacin acts on DNA gyrase and toposiomerase IV, enzymes which, like human topoisomerase, prevents the excessive supercoiling of DNA during replication or transcription. By inhibiting their function, the drug thereby inhibits normal cell division.


Quinolone(s) (QNs) is widely used in infection therapy due to its good antimicrobial characteristics. However, QNs-induced arthropathy of immature animals has led to restrictions on the therapeutic use of these antimicrobial agents. The exact mechanism(s) of QNs-induced chondrotoxicity remain unknown. In the present study, .../the authors/ investigated the possible mechanism of ofloxacin (one typical QNs)-induced injuries of chondrocytes. Juvenile rabbit joint chondrocytes cultured in alginate microspheres were incubated with ofloxacin at concentrations of 0, 2, 5, 10, 20, and 40 microg/mL for up to 96 hr. Concentration of 10 microg/mL ofloxacin induced apoptosis of chondrocyte with visible apoptotic signs, including degradation of poly(ADP-ribose) polymerase, caspase-3 activation, and DNA ladder formation. Furthermore, extracellular signal-regulated kinase 1/2 (phospho-ERK1/2) and growth factor receptor-bound protein 2 (Grb2) were significantly reduced, and similar changes were also observed in the beta(1)-integrin receptor as assessed by immunoblotting. However, the mRNA level of beta(1)-integrin obtained from reverse transcription-polymerase chain reaction remained unchanged. Results of beta(1)-integrin immunoprecipitation have also shown that beta(1)-integrin did not interact with activated intracellular signaling proteins. In addition, ofloxacin did not induce apoptosis and decrease beta(1)-integrin expression in chondrocytes supplemented with Mg(2+), and the ofloxacin-induced apoptosis was caspase-8-dependent, inhibition of which did not affect the expression mode of phospho-ERK1/2 and beta(1)-integrin. Our results demonstrate that ofloxacin affects beta(1)-integrin receptor functions and the ERK mitogen-activated protein kinase signaling pathway, causing caspase-8-dependent apoptosis after exposure of 48 hr.

PMID:17400890 Sheng ZG et al; J Pharmacol Exp Ther 322 (1): 155-65 (2007)


Quinolones are widely used in infection therapy due to their good antimicrobial characteristics. However, there potential joint chondrotoxicity on immature animals has stood in the way of the therapeutic application of these agents, the exact mechanism of which is still unclear. This study was undertaken to investigate the role of oxidative damage in ofloxacin (one typical quinolones)-induced arthropathy. Chondrocytes from juvenile rabbit joints were incubated with ofloxacin at concentrations of 0, 5, 10, 20, 40 and 80 ug/mL, respectively. The extent of oxidative damage was assessed by measuring the reactive oxygen species level, activities of antioxidant enzymes, and oxidative damage to some macromolecules. It was observed that ofloxacin induced a concentration-dependent increase in intracellular reactive oxygen species production, which may be an early mediator of ofloxacin cytotoxicity. Similarly, ofloxacin resulted in a significant lipid peroxidation, revealed by a concentration-dependent increase in the level of thiobarbituric acid reactive substances. At the same time, ofloxacin induced DNA damage in a concentration-dependent manner for 24 hr measured by comet assay, which may be a cause for overproduction of reactive oxygen species. Furthermore, antioxidant enzyme activities, such as glutathione peroxidase (GPx), catalase and superoxide dismutase (SOD), were rapidly decreased after treatment with ofloxacin. In addition, SOD decline and reactive oxygen species production were strongly inhibited, and the loss in cell viability was partly abated by additional glutathione (GSH), N-acetylcysteine (NAC) and dithiothreitol (DTT). In conclusion, these results clearly demonstrated that ofloxacin could induce oxidative stress, lipid peroxidation and DNA oxidative damage to chondrocytes.

PMID:19818344 Li Q et al; Eur J Pharmacol 626 (2-3): 146-53 (2010)


Ofloxacin is a quinolone antimicrobial agent. The mechanism of action of ofloxacin and other fluoroquinolone antimicrobials involves inhibition of bacterial topoisomerase IV and DNA gyrase (both of which are type II topoisomerases), enzymes required for DNA replication, transcription, repair and recombination. Ofloxacin has in vitro activity against a wide range of gram-negative and gram-positive microorganisms. Ofloxacin is often bactericidal at concentrations equal to or slightly greater than inhibitory concentrations. Fluoroquinolones, including ofloxacin, differ in chemical structure and mode of action from aminoglycosides, macrolides and beta-lactam antibiotics, including penicillins. Fluoroquinolones may, therefore, be active against bacteria resistant to these antimicrobials. Resistance to ofloxacin due to spontaneous mutation in vitro is a rare occurrence (range: 10(-9) to 10(-11)). Although cross-resistance has been observed between ofloxacin and some other fluoroquinolones, some microorganisms resistant to other fluoroquinolones may be susceptible to ofloxacin.

US Natl Inst Health; DailyMed. Current Medication Information for OFLOXACIN tablet, film coated (January 2012). Available from, as of February 28, 2012: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=95b9fc17-9c94-4762-910c-df0bb0b2aa85


Fluoroquinolones prolong the QT interval by blocking voltage-gated potassium channels, especially the rapid component of the delayed rectifier potassium current I(Kr), expressed by HERG (the human ether-a-go-go-related gene). According to the available case reports and clinical studies, moxifloxacin carries the greatest risk of QT prolongation from all available quinolones in clinical practice and it should be used with caution in patients with predisposing factors for Torsades de pointes (TdP).

PMID:22156660 Briasoulis A et al; Cardiology 120 (2): 103-10 (2011)


API SUPPLIERS

read-more
read-more

01

Global Pharma Healthcare

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothGlobal Pharma Healthcare: Setting the global benchmark in quality, innovation, and care

Flag India
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
CB

02

Temad Co

Iran

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothTemad- We think of world-class quality.

Flag Iran
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Temad

03

Jai Radhe Sales

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothJai Radhe Sales is your partner for all your sourcing needs.

Flag India
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Jai Radhe Sales

04

Century Pharmaceuticals

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothCentury has been an API manufacturer for over 40 years & is the partner of choice for multipurpose custom manufacturing projects.

Flag India
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Century Company Banner

05

Neuland Laboratories

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothNeuland Laboratories- A dedicated 100% API provider.

Flag India
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC arrow-down KDMF VMF Others AUDIT arrow-down
Neuland

06

Octavius Pharma Pvt. Ltd

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothOctavius Pharma has been empowering lives since 1980 by providing quality products like DC granules, APIs and FDFs.

Flag India
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Octavius Pharma

07

Vital Laboratories Private Limited

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothVital Laboratories – Trusted Global API Manufacturer of Quinine, Hyoscine, Antimalarials & Vitamins

Flag India
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
CB

08

Cerata Pharmaceuticals LLP

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothCerata Pharmaceuticals LLP: WHO-GMP Certified Leading Manufacturer & Exporter of Steroid-Hormone & Peptide APIs From India.

Flag India
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Company Banner

09

Mahima Life Sciences

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Arvo
Not Confirmed
arrow

Mahima Life Sciences

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Arvo
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

10

Turtle Pharma

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Arvo
Not Confirmed
arrow

Turtle Pharma

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Arvo
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

USDMF

read-more
read-moreread-more

01

Arvo
Not Confirmed

01

Arvo
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2016-03-25

Pay. Date : 2016-03-02

DMF Number : 14928

Submission : 2000-06-19

Status : Active

Type : II

blank

02

Cipla Ltd

India

USDMF

arrow
Arvo
Not Confirmed

02

Cipla Ltd

India
arrow
Arvo
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 16753

Submission : 2003-08-11

Status : Inactive

Type : II

blank

03

Arvo
Not Confirmed

04

Arvo
Not Confirmed

05

Arvo
Not Confirmed

06

Arvo
Not Confirmed

07

Arvo
Not Confirmed

08

Quimica Sintetica Sa

Spain

USDMF

arrow
Arvo
Not Confirmed

08

Arvo
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2013-01-03

Pay. Date : 2012-12-27

DMF Number : 14767

Submission : 2000-03-08

Status : Active

Type : II

blank

09

Arvo
Not Confirmed
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

CEP/COS

read-more
read-moreread-more
Flag U.S.A
Digital Content Digital Content
R0-CEP 2001-436 - Rev 02
Withdrawn by Holder
Chemical
2005-03-24
2008-08-28
1455
blank

01

Arvo
Not Confirmed
arrow
arrow
Arvo
Not Confirmed

Certificate Number : R0-CEP 2001-436 - Rev 02

Status : Withdrawn by Holder

Issue Date : 2005-03-24

Type : Chemical

Substance Number : 1455

blank

02

Arvo
Not Confirmed
arrow
arrow
Arvo
Not Confirmed

Certificate Number : R0-CEP 2002-029 - Rev 01

Status : Expired

Issue Date : 2004-10-13

Type : Chemical

Substance Number : 1455

blank

03

Arvo
Not Confirmed
arrow
arrow
Arvo
Not Confirmed

Certificate Number : CEP 2003-210 - Rev 04

Status : Valid

Issue Date : 2024-12-20

Type : Chemical

Substance Number : 1455

blank

04

Arvo
Not Confirmed
arrow

05

Arvo
Not Confirmed
arrow

06

Arvo
Not Confirmed
arrow
arrow
Arvo
Not Confirmed

Certificate Number : R1-CEP 2002-146 - Rev 02

Status : Withdrawn by Holder

Issue Date : 2011-02-07

Type : Chemical

Substance Number : 1455

blank

07

Arvo
Not Confirmed
arrow
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

JDMF

read-more
read-moreread-more

01

Arvo
Not Confirmed
arrow
arrow
Arvo
Not Confirmed

ofloxacin

Registration Number : 217MF10957

Registrant's Address : 1-10-1 Mukaihama, Akita City, Akita Prefecture

Initial Date of Registration : 2005-11-14

Latest Date of Registration : 2007-04-27

blank

02

Arvo
Not Confirmed
arrow
arrow
Arvo
Not Confirmed

ofloxacin

Registration Number : 217MF11127

Registrant's Address : Plot No. 90, Sector 32, Gurgaon, Haryana 122 001, India

Initial Date of Registration : 2005-12-05

Latest Date of Registration : 2009-07-30

blank

03

Arvo
Not Confirmed
arrow
arrow
Arvo
Not Confirmed

ofloxacin

Registration Number : 225MF10070

Registrant's Address : 333, Jiangnan Road, Hengdian, Dongyang, Zhejiang, 322118, China.

Initial Date of Registration : 2013-04-18

Latest Date of Registration : 2013-04-18

blank

04

Arvo
Not Confirmed
arrow
arrow
Arvo
Not Confirmed

ofloxacin

Registration Number : 218MF10567

Registrant's Address : 333, Jiangnan Road, Hengdian, Dongyang, Zhejiang, 322118, China.

Initial Date of Registration : 2006-06-15

Latest Date of Registration : 2006-06-15

blank

05

Arvo
Not Confirmed
arrow
arrow
Arvo
Not Confirmed

ofloxacin

Registration Number : 229MF10021

Registrant's Address : 23rd Floor, Chamber of Commerce Building North Laodong Road, Huangyan, Zhejiang, Chin...

Initial Date of Registration : 2017-01-30

Latest Date of Registration : 2021-03-15

blank

06

Arvo
Not Confirmed
arrow
arrow
Arvo
Not Confirmed

Ofloxacin "Koa"

Registration Number : 218MF10326

Registrant's Address : 23rd Floor, Chamber of Commerce Building North Loading Road, Huangyan, Zhejiang, Chin...

Initial Date of Registration : 2006-03-09

Latest Date of Registration : 2008-04-21

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

EU WC

read-more
read-moreread-more

01

AOCS Annual Meeting
Not Confirmed
arrow
arrow
AOCS Annual Meeting
Not Confirmed

Ofloxacin BP/IP/USP/Ph Eur

Date of Issue : 2024-11-05

Valid Till : 2024-11-04

Written Confirmation Number : WC-0594

Address of the Firm : Plot No. C-198, G.I.D.C., Saykha, Taluka -Vagra, Dist -Bharuch -392140, Gujarat,...

blank

02

AOCS Annual Meeting
Not Confirmed
arrow
arrow
AOCS Annual Meeting
Not Confirmed

Ofloxacin USP/Ph.Eur.

Date of Issue : 2025-08-05

Valid Till : 2028-06-02

Written Confirmation Number : WC-0011

Address of the Firm : Village Toansa, P.O. Rail Majra, Tehsil Balachaur, District S.B.S. Nagar (Punjab...

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

NDC API

read-more
read-moreread-more

01

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothNeuland Laboratories- A dedicated 100% API provider.

Flag India
Digital Content Digital Content

OFLOXACIN

NDC Package Code : 58032-0090

Start Marketing Date : 2017-12-13

End Marketing Date : 2026-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

Neuland

02

Arvo
Not Confirmed
arrow
arrow
Arvo
Not Confirmed

OFLOXACIN

NDC Package Code : 59116-1820

Start Marketing Date : 2012-10-26

End Marketing Date : 2026-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank

03

Arvo
Not Confirmed
arrow
arrow
Arvo
Not Confirmed

9-PIPERAZINO OFLOXACIN

NDC Package Code : 53069-0440

Start Marketing Date : 2000-03-08

End Marketing Date : 2026-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Suppliers

read-more
read-more

01

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothGlobal Pharma Healthcare: Setting the global benchmark in quality, innovation, and care

Flag India
Digital Content Digital Content

Ofloxacin

About the Company : Global Pharma Healthcare, established in 1999, has nearly three decades of experience in producing APIs, finished formulations, and nutraceuticals at its EU-GMP and WHO-GMP certifi...

Global Pharma Healthcare, established in 1999, has nearly three decades of experience in producing APIs, finished formulations, and nutraceuticals at its EU-GMP and WHO-GMP certified facilities in Chennai. The company supports contract manufacturing from development through commercial supply. With 700+ registrations and strong regulatory capability, it supplies products to over 40 countries across Asia, Africa, CIS, Europe, and LATAM. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.
CB

02

Temad Co

Iran
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothTemad- We think of world-class quality.

Flag Iran
Digital Content Digital Content

Ofloxacin

About the Company : Temad Co., established in 1997, is one of Iran's largest API producers and an innovative manufacturer of narcotic and non-narcotic products in the Middle East. It complies with Ira...

Temad Co., established in 1997, is one of Iran's largest API producers and an innovative manufacturer of narcotic and non-narcotic products in the Middle East. It complies with Iranian GMP and international standards like ISO 9001/14001/17025/45001 and OHSAS 18001. Temad manufactures over 115 pharmaceutical products, meeting GMP and WHO standards, and exports to 45 countries worldwide. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.
Temad

03

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothJai Radhe Sales is your partner for all your sourcing needs.

Flag India
Digital Content Digital Content

Ofloxacin

About the Company : Jai Radhe Sales, founded in 1999, is a global distributor specializing in high-quality pharmaceutical ingredients from India. It offers complete sourcing solutions, technical and r...

Jai Radhe Sales, founded in 1999, is a global distributor specializing in high-quality pharmaceutical ingredients from India. It offers complete sourcing solutions, technical and regulatory support, and strives for global standards. Known for quality and affordability, it has established a niche through innovative methods and exports to nearly every continent. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.
Jai Radhe Sales

04

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothCentury has been an API manufacturer for over 40 years & is the partner of choice for multipurpose custom manufacturing projects.

Flag India
Digital Content Digital Content

Ofloxacin

About the Company : Century Pharmaceuticals, established in 1982, has 40 years of experience manufacturing APIs for major pharma companies in India and abroad. Its products are made in compliance with...

Century Pharmaceuticals, established in 1982, has 40 years of experience manufacturing APIs for major pharma companies in India and abroad. Its products are made in compliance with cGMP, 21 CFR, and ICH guidelines, and it also produces intermediates and develops new APIs as per client requirements. The company conducts biotechnological research on human therapeutic proteins, including treatments for asthma, mastocytosis, and basophilic leukemia, and supplies research-grade biotech and animal health products. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.
Century Company Banner

05

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothOctavius Pharma has been empowering lives since 1980 by providing quality products like DC granules, APIs and FDFs.

Flag India
Digital Content Digital Content

Ofloxacin

About the Company : Octavius Pharma is a global leader in Directly Compressible Granules with over 45 years of experience in formulation development, manufacturing, and commercialization. Its portfoli...

Octavius Pharma is a global leader in Directly Compressible Granules with over 45 years of experience in formulation development, manufacturing, and commercialization. Its portfolio includes DC granules, herbal and food supplements, APIs, and finished formulations such as tablets, capsules, syrups, and ointments. With WHO-GMP certification and a DSIR-certified R&D center, the company ensures quality and innovation, exporting to LATAM, the Middle East, Africa, Asia, and CIS regions, and offering formulation and marketing support. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.
Octavius Pharma

06

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothVital Laboratories – Trusted Global API Manufacturer of Quinine, Hyoscine, Antimalarials & Vitamins

Flag India
Digital Content Digital Content

Ofloxacin

About the Company : Vital Laboratories is an API and intermediates manufacturer established in 1998, beginning with quinine derivatives. Today, it is a global leader in quinine and hyoscine derivative...

Vital Laboratories is an API and intermediates manufacturer established in 1998, beginning with quinine derivatives. Today, it is a global leader in quinine and hyoscine derivatives, antimalarials, and vitamins, offering over 60 synthetic and phytochemistry-based APIs. With backward integration from KSMs and two WHO GMP–approved manufacturing facilities in Vapi, India, accredited by leading global regulators, Vital delivers scale, efficiency, cost leadership, and reliable global supply security. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.
CB

07

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothCerata Pharmaceuticals LLP: WHO-GMP Certified Leading Manufacturer & Exporter of Steroid-Hormone & Peptide APIs From India.

Flag India
Digital Content Digital Content

Ofloxacin

About the Company : Cerata Pharmaceuticals LLP is a WHO-GMP certified pharmaceutical API manufacturer based in Gujarat, India. We specialize in the development and manufacturing of high-quality APIs a...

Cerata Pharmaceuticals LLP is a WHO-GMP certified pharmaceutical API manufacturer based in Gujarat, India. We specialize in the development and manufacturing of high-quality APIs and High Potency APIs, adhering to the highest global quality and compliance standards. As a fully integrated company, Cerata supports the complete API lifecycle from development to commercialization. Our products are trusted by pharmaceutical companies in over 40 countries, reflecting our strong global presence and commitment to excellence. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.
Company Banner

08

Arvo
Not Confirmed
arrow
arrow
Arvo
Not Confirmed

Ofloxacin

About the Company : Asia Pioneer Pharmaceuticals is a leading supplier of fine chemicals, pharmaceutical intermediates, active pharmaceutical ingredients and other compounds. It also offers finished p...

Asia Pioneer Pharmaceuticals is a leading supplier of fine chemicals, pharmaceutical intermediates, active pharmaceutical ingredients and other compounds. It also offers finished product licensing, custom manufacturing and outsourcing services. In partnership with state-of-the-art manufacturers in China, Asia Pioneer provides world-class quality products at excellent value, in full compliance with standards required by leading regulatory agencies in the USA and Europe.
blank

09

Biotechnica DWC

Algeria
Arvo
Not Confirmed
arrow

Biotechnica DWC

Algeria
arrow
Arvo
Not Confirmed

Ofloxacin

About the Company : BIOTECHNICA DWC LLC has carved a niche for itself in providing value added compliance, regulatory qualification, project management and GDP guidance services to pharma companies al...

BIOTECHNICA DWC LLC has carved a niche for itself in providing value added compliance, regulatory qualification, project management and GDP guidance services to pharma companies all over the world. Biotechnica is an integrated global solution provider from design to implementation of industrial projects in the areas of Pharmaceuticals,Agri-food ,Cosmetics and Nutrition. With more than 25 years of experience in the assembly of plants, particularly in the pharmaceutical sector, we accompany our customers in the various stages of their projects – E-CTD Dossieers – Raw Materiels – Equipements – Accessories – Packaging – Distribution.
blank

10

Arvo
Not Confirmed
arrow
arrow
Arvo
Not Confirmed

Ofloxacin

About the Company : Pharma Noble Chem Ltd, a subsidiary of Noble Group, is a leading manufacturer of APIs, API intermediates, and specialty chemicals. Committed to quality and innovation, we offer hig...

Pharma Noble Chem Ltd, a subsidiary of Noble Group, is a leading manufacturer of APIs, API intermediates, and specialty chemicals. Committed to quality and innovation, we offer high-quality products and reliable CRAMS for the pharmaceutical industry. Founded in 1984 by Mohammed Akhtar, Noble Group has expanded globally, with a strong presence in India, Saudi Arabia, UAE, Oman, China, Singapore, Myanmar, Laos, Azerbaijan, and Qatar. Our reputation is built on excellence, innovation, and impact across multiple sectors worldwide.
blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Europe

read-more
read-more

01

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothEUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

Flag France
Digital Content Digital Content

Regulatory Info : Deregistered

Registration Country : Sweden

Ofloxacin

Brand Name : Tarivid

Dosage Form : Tablet

Dosage Strength : 400mg

Packaging :

Approval Date : 24-01-1992

Application Number : 1.99E+13

Regulatory Info : Deregistered

Registration Country : Sweden

EUROAPI Compnay Banner

02

Sanofi S.R.L

France
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

Flag France
Digital Content Digital Content

Regulatory Info : Withdrawn

Registration Country : Malta

Ofloxacin

Brand Name : Oflocet Ear

Dosage Form : Ear Drop Solution

Dosage Strength : 1.5MG

Packaging :

Approval Date : 2005-09-29

Application Number :

Regulatory Info : Withdrawn

Registration Country : Malta

Sanofi Company Banner

03

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

Flag France
Digital Content Digital Content

Regulatory Info : Deregistered

Registration Country : Sweden

Ofloxacin

Brand Name : Tarivid

Dosage Form : Tablet

Dosage Strength : 200mg

Packaging :

Approval Date : 26-10-1990

Application Number : 1.99E+13

Regulatory Info : Deregistered

Registration Country : Sweden

Sanofi Company Banner

04

Ofloxacin

Brand Name : Uniflox

Dosage Form : Ear Drops, Solution, Eye Drops, Solution

Dosage Strength : 3MG/ML

Packaging :

Approval Date : 2024-08-29

Application Number :

Regulatory Info : Authorised

Registration Country : Malta

Abbvie Company Banner

05

Ofloxacin

Brand Name : Exocin

Dosage Form : Eye Drop Solution

Dosage Strength : 3MG

Packaging :

Approval Date : 01-07-1999

Application Number : 62560

Regulatory Info : Authorized

Registration Country : Spain

Abbvie Company Banner

06

ALLERGAN

U.S.A

Ofloxacin

Brand Name : Exocin

Dosage Form :

Dosage Strength : Pom Oftalm 3,5 G 0,3%  

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Italy

Abbvie CB

07

ALLERGAN

U.S.A

Ofloxacin

Brand Name : Exocin

Dosage Form :

Dosage Strength : Coll 10 Ml 0.3%  

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Italy

Abbvie CB

08

Arvo
Not Confirmed
arrow
arrow
Arvo
Not Confirmed

Ofloxacin

Brand Name : Ofloxacino Altan

Dosage Form : Perfusion Solution

Dosage Strength : 2MG

Packaging :

Approval Date : 19-04-2006

Application Number : 67741

Regulatory Info : Authorized

Registration Country : Spain

blank

09

Horus Pharma

France
Arvo
Not Confirmed
arrow

Horus Pharma

France
arrow
Arvo
Not Confirmed

Ofloxacin

Brand Name : MONOOX®

Dosage Form : Eye Drops

Dosage Strength : 1.5mg/0.5ml

Packaging :

Approval Date : 08-05-2025

Application Number :

Regulatory Info :

Registration Country : Moldova

blank

10

Arvo
Not Confirmed
arrow
arrow
Arvo
Not Confirmed

Ofloxacin

Brand Name :

Dosage Form : FILM COATED TABLET

Dosage Strength : 400MG

Packaging : 5 Or 10 Tablets

Approval Date :

Application Number :

Regulatory Info : Generic

Registration Country : Turkey

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Australia

read-more
read-more

01

Ofloxacin

Brand Name : Ocuflox

Dosage Form : eye drops

Dosage Strength : 0.3%

Packaging : 1

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Australia

Abbvie Company Banner

02

Ofloxacin

Brand Name : Ocuflox

Dosage Form : eye drops

Dosage Strength : 0.3%

Packaging : 1

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Australia

Abbvie Company Banner
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Related Excipient Companies

Upload your portfolio for free, ask us

Excipients by Applications

Click here to find the perfect excipient manufacturers by their capabilities

Coating Systems & Additives

read-more
read-more

Fillers, Diluents & Binders

read-more
read-more

Direct Compression

read-more
read-more

Solubilizers

read-more
read-more

Controlled & Modified Release

read-more
read-more

Granulation

read-more
read-more

Thickeners and Stabilizers

read-more
read-more

Parenteral

read-more
read-more

Lubricants & Glidants

read-more
read-more

Disintegrants & Superdisintegrants

read-more
read-more

Topical

read-more
read-more

Film Formers & Plasticizers

read-more
read-more

Co-Processed Excipients

read-more
read-more

Emulsifying Agents

read-more
read-more

Empty Capsules

read-more
read-more

API Stability Enhancers

read-more
read-more

Taste Masking

read-more
read-more

Vegetarian Capsules

read-more
read-more

Surfactant & Foaming Agents

read-more
read-more

Chewable & Orodispersible Aids

read-more
read-more

Rheology Modifiers

read-more
read-more

Coloring Agents

read-more
read-more

Digital Content read-more

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Market Place

Do you need sourcing support? Ask us

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ANALYTICAL

Upload your methods for free, ask us

ABOUT THIS PAGE

Looking for 82419-36-1 / Ofloxacin API manufacturers, exporters & distributors?

Ofloxacin manufacturers, exporters & distributors 1

41

PharmaCompass offers a list of Ofloxacin API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Ofloxacin manufacturer or Ofloxacin supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Ofloxacin manufacturer or Ofloxacin supplier.

API | Excipient name

Ofloxacin

Synonyms

82419-36-1, Floxin, Tarivid, Ofloxacine, Oxaldin, Ocuflox

Cas Number

82419-36-1

Unique Ingredient Identifier (UNII)

A4P49JAZ9H

About Ofloxacin

A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.

Floxal Manufacturers

A Floxal manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Floxal, including repackagers and relabelers. The FDA regulates Floxal manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Floxal API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Floxal manufacturers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PhamaCompass.

Floxal Suppliers

A Floxal supplier is an individual or a company that provides Floxal active pharmaceutical ingredient (API) or Floxal finished formulations upon request. The Floxal suppliers may include Floxal API manufacturers, exporters, distributors and traders.

click here to find a list of Floxal suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.

Floxal USDMF

A Floxal DMF (Drug Master File) is a document detailing the whole manufacturing process of Floxal active pharmaceutical ingredient (API) in detail. Different forms of Floxal DMFs exist exist since differing nations have different regulations, such as Floxal USDMF, ASMF (EDMF), JDMF, CDMF, etc.

A Floxal DMF submitted to regulatory agencies in the US is known as a USDMF. Floxal USDMF includes data on Floxal's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Floxal USDMF is kept confidential to protect the manufacturer’s intellectual property.

click here to find a list of Floxal suppliers with USDMF on PharmaCompass.

Floxal JDMF

The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.

The Floxal Drug Master File in Japan (Floxal JDMF) empowers Floxal API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).

PMDA reviews the Floxal JDMF during the approval evaluation for pharmaceutical products. At the time of Floxal JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.

click here to find a list of Floxal suppliers with JDMF on PharmaCompass.

Floxal KDMF

In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.

Pharmaceutical companies submit a Floxal Drug Master File in Korea (Floxal KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Floxal. The MFDS reviews the Floxal KDMF as part of the drug registration process and uses the information provided in the Floxal KDMF to evaluate the safety and efficacy of the drug.

After submitting a Floxal KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Floxal API can apply through the Korea Drug Master File (KDMF).

click here to find a list of Floxal suppliers with KDMF on PharmaCompass.

Floxal CEP

A Floxal CEP of the European Pharmacopoeia monograph is often referred to as a Floxal Certificate of Suitability (COS). The purpose of a Floxal CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Floxal EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Floxal to their clients by showing that a Floxal CEP has been issued for it. The manufacturer submits a Floxal CEP (COS) as part of the market authorization procedure, and it takes on the role of a Floxal CEP holder for the record. Additionally, the data presented in the Floxal CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Floxal DMF.

A Floxal CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Floxal CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.

click here to find a list of Floxal suppliers with CEP (COS) on PharmaCompass.

Floxal WC

A Floxal written confirmation (Floxal WC) is an official document issued by a regulatory agency to a Floxal manufacturer, verifying that the manufacturing facility of a Floxal active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Floxal APIs or Floxal finished pharmaceutical products to another nation, regulatory agencies frequently require a Floxal WC (written confirmation) as part of the regulatory process.

click here to find a list of Floxal suppliers with Written Confirmation (WC) on PharmaCompass.

Floxal NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Floxal as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for Floxal API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture Floxal as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain Floxal and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Floxal NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of Floxal suppliers with NDC on PharmaCompass.

Floxal GMP

Floxal Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Floxal GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Floxal GMP manufacturer or Floxal GMP API supplier for your needs.

Floxal CoA

A Floxal CoA (Certificate of Analysis) is a formal document that attests to Floxal's compliance with Floxal specifications and serves as a tool for batch-level quality control.

Floxal CoA mostly includes findings from lab analyses of a specific batch. For each Floxal CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Floxal may be tested according to a variety of international standards, such as European Pharmacopoeia (Floxal EP), Floxal JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Floxal USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty